Directory Category: Drug Discovery
Ampio‪s Phase I Study for Inhaled Ampion Advances to Completing Enrollment of Covid-19 Patients With Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology based therapies for
prevalent inflammatory conditions, announced today that its AP-014 Phase
I inhaled Ampion clinical study in COVID-19 patients is proceeding to
full open enrollment following clearance by the Safety Monitoring
Committee (SMC), which found Ampion to be safe and well-tolerated after
reviewing results from the first three treatment groups.
Ampio‪s Phase I Study for Inhaled Ampion Advances to Completing Enrollment of Covid-19 Patients With Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology based therapies for
prevalent inflammatory conditions, announced today that its AP-014 Phase
I inhaled Ampion™ clinical study in COVID-19 patients is proceeding to
full open enrollment following clearance by the Safety Monitoring
Committee (SMC).
